Compare KB Financial Group, Inc. (KB) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Pfizer Inc — how do they compare? KB Financial Group, Inc. trades at $121.96 (market cap $44.15B), while Pfizer Inc trades at $27.77 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 3.6× KB Financial Group, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Pfizer Inc for 158 Days on average.
| KB | PFE | |
|---|---|---|
Market Cap | $44.15B | $159.59B |
Volume | 131,395 | 30,937,010 |
Sector | Financials | Health |
52-Week High | $132.88 | $29.02 |
52-Week Low | $77.50 | $23.67 |
Typical Hold Time | 33 Days | 158 Days |
Enterprise Value | $215.53T | $211.09B |
Dividend Yield | 2.65% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group trades at $124.73, showing minimal daily movement with a slight decline of 0.02%. The stock exhibits neutral technical signals while maintaining strong fundamental performance with consistent earnings beats and improving profitability. Recent quarterly results exceeded expectations, with Q2 2026 EPS of $3.79 beating estimates of $3.51. The company demonstrates solid revenue growth, climbing from $17.77T in 2022 to $21.23T in 2025, with net income margins expanding to 27.47%.
KB presents an attractive value proposition with a P/E of 9.92 and P/B of 0.97, trading below book value. Analyst sentiment is mixed with 33% buy ratings but strong institutional interest. Key risks include banking sector volatility and interest rate sensitivity, while opportunities lie in South Korea's outperforming market and the company's expanding non-banking activities driving fee income growth.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
